Skip to search formSkip to main contentSkip to account menu

LY353381hydrochloride

Known as: LY353381.HCL, LY353381 hydrochloride, SERM-3 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

LY 353381arzoxifene hydrochloride

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2004
2004
Breast cancer chemoprevention Phase IB evaluation of biomarker modulation by arzoxifene, a third generation selective estrogen receptor modulator.
1015 Background: Arzoxifene (LY353381.HCl) is a new selective estrogen receptor modulator, SERM, with strong breast antiestrogen… 
2004
2004
Breast cancer chemoprevention Phase IB evaluation of biomarker modulation by arzoxifene, a third generation selective estrogen receptor modulator
1015 Background: Arzoxifene (LY353381.HCl) is a new selective estrogen receptor modulator, SERM, with strong breast antiestrogen… 
Review
2002
Review
2002
Current status and future innovations of hormonal agents, chemotherapy and investigational agents in endometrial cancer
The median survival of women with advanced or recurrent endometrial cancer is less than one year. Only half the women with early… 
2001
2001
Selective Estrogen Receptor Modulator LY353381.HCl-Mediated Neuroprotection and BCL-2 Expression After Experimental Stroke
62 Estrogen replacement in ovariectomized rats reduces cerebral tissue infarction sustained after experimental stroke. We… 
2000
2000
LY353381.HCl, a Selective Estrogen Receptor Modulator, and Experimental Stroke
Background and Purpose The impact of postmenopausal estrogen replacement therapy on stroke prevention and stroke severity remains… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)